Given that gefitinib and erlotinib generate ROS in a process blocked by antioxidant and PAFR antagonist (Figure 1), and our previous reports demonstrating that pro-oxidative stressors induce MVP release in a PAFR-dependent manner [34,35,36], we tested our working hypothesis if these targeted therapies can induce MVP release in lung cancer cells. Here, PTAFR is linked to lung cancer.